Clinical research status of atrial fibrillation related ischemic stroke

Chinese Journal of Contemporary Neurology and Neurosurgery

Xue-song TU¹ 

[1] Department of Neurology, Cerebrovascular Disease Hospital, Beijing 100039, China;

关键词: Stroke;    Atrial fibrillation;    Platelet aggregation inhibitors;    Anticoagulants;    Review;   

DOI  :  

来源: DOAJ

【 摘 要 】

Atrial fibrillation (AF) is the independent risk factor for acute ischemicstroke. AF-related ischemic stroke account for 20% of total ischemic stroke.Risk factors include old age (≥ 75 years), hypertension, diabetes mellitus,recent heart failure, ischemic stroke and transient ischemic attack (TIA)history. Risk evaluation system mainly contains CHADS₂ andCHA₂DS₂-VAS_c. The establishment of riskevaluation system is favorable for evaluating the future risk of stroke, anddeciding to take which kind of treatment measures: anticoagulant therapy forhigh, moderate risk; anti-platelet aggregation treatment or no treatment for lowrisk. Warfarin is still the main anticoagulant drug at present. New oralanticoagulants (NOACs) have advantages such as low incidence of stroke, lowbleeding rate, no need to monitor, however, they are lack of validation frommulticenter, large sample randomized controlled trials.

 

DOI: 10.3969/j.issn.1672-6731.2015.01.005

【 授权许可】

Unknown